Last reviewed · How we verify
Lopinavir/ritonavir + tenofovir + nucleoside
Lopinavir/ritonavir + tenofovir + nucleoside is a Antiretroviral combination therapy (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve and treatment-experienced patients.
This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle.
This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Lopinavir/ritonavir + tenofovir + nucleoside |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Antiretroviral combination therapy (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Lopinavir and ritonavir are protease inhibitors that prevent HIV protease from cleaving viral polyproteins, while tenofovir and the nucleoside reverse transcriptase inhibitor block reverse transcriptase to prevent conversion of viral RNA to DNA. Together, these agents target complementary steps in HIV replication to suppress viral load.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Lipid abnormalities (elevated triglycerides/cholesterol)
- Hepatotoxicity
- Renal impairment (tenofovir-related)
- Headache
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Post-Exposure Prophylaxis in Health Care Workers (PHASE4)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (NA)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lopinavir/ritonavir + tenofovir + nucleoside CI brief — competitive landscape report
- Lopinavir/ritonavir + tenofovir + nucleoside updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Lopinavir/ritonavir + tenofovir + nucleoside
What is Lopinavir/ritonavir + tenofovir + nucleoside?
How does Lopinavir/ritonavir + tenofovir + nucleoside work?
What is Lopinavir/ritonavir + tenofovir + nucleoside used for?
Who makes Lopinavir/ritonavir + tenofovir + nucleoside?
What drug class is Lopinavir/ritonavir + tenofovir + nucleoside in?
What development phase is Lopinavir/ritonavir + tenofovir + nucleoside in?
What are the side effects of Lopinavir/ritonavir + tenofovir + nucleoside?
What does Lopinavir/ritonavir + tenofovir + nucleoside target?
Related
- Drug class: All Antiretroviral combination therapy (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Compare: Lopinavir/ritonavir + tenofovir + nucleoside vs similar drugs
- Pricing: Lopinavir/ritonavir + tenofovir + nucleoside cost, discount & access